Skip to main content
Jennison Associates logoJennison Associates  logo
  • About Us
  • Equity

    • Large Cap Growth
    • Global
    • International
    • Emerging Markets
    • Mid Cap Growth
    • Small Cap Core

    Equity

    • SMid Cap Core
    • Large Cap Value
    • Global Equity Income
    • Rising Dividend

    Thematic Equity

    • Health Sciences
    • Utility Equity
    • Global Infrastructure
    • Global Natural Resources
    • MLP (Master Limited Partnerships)
    • Financial Services
    Fixed Income
    • Active Long Duration
    • Active Core
    • Active Intermediate
    • Stable Value
    • LDI
  • ESG Overview
    • Integration
    • Proxy Voting
    • Engagement
    • Corporate Citizenship
  • Perspectives
  • Contact Us
  • Client Login
Financial chart on digital display
ESG

Jiangsu Hengrui: Secular Tailwinds in Chinese HealthcareJiangsuHengrui:SecularTailwindsinChineseHealthcare

Analyzing product governance concerns.

Jiangsu Hengrui

Secular tailwinds in Chinese healthcare

Jiangsu Hengrui is one of China’s largest pharmaceutical companies. Its areas of focus include oncology and endocrinology, and it has multiple clinical-stage assets in its pipeline. We maintain a position in Jiangsu Hengrui as we believe that China’s increased focus on pharmaceutical and biotech innovation should bode well for the company as a successful drug innovator.

A tale of two risk ratings

In the course of our due diligence, we found that in December 2019, a third-party vendor had assigned Jiangsu Hengrui an overall Severe ESG risk rating, citing inconsistent marketing practices and quality and safety issues related to manufacturing irregularities, resulting in costly product recalls. While we do not invest based on third-party ESG risk ratings, we view them as a useful point of reference. Our analysis led us to form a less severe risk assessment due to our forward looking view, which anticipated that the changing composition of Hengrui’s drug pipeline would force improvements in product governance.

Jiangsu Hengrui is one of the first large cap pharma companies in China to shift its R&D pipeline focus to innovative drugs, which are subject to tighter regulatory scrutiny. As a result, the company must adhere to stricter government, clinical, commercialization, and marketing standards or risk losing its ability to commercialize its drug pipeline. Further, Jiangsu Hengrui is beginning to compete on a global stage and in order to succeed it must adhere to global standards, including disclosing clinical trial data which historically it has not done.

Engagement helps solidify our view

As of November 2020, the company is running a global trial for liver cancer therapeutics under U.S. Food and Drug Administration (FDA) oversight, which requires data disclosure and review of safety and efficacy. Additionally, in June 2020 the company’s head of R&D provided a pipeline update to investors. On this call the company reviewed its American Society of Clinical Oncology (ASCO) abstracts as well as pending negotiations with the Chinese government on central procurement (GPO) for injectible and generic drugs. We were encouraged by these signs of progress in Jiangsu’s ability to meet more stringent industry requirements. With respect to manufacturing irregularities, our analyst concluded that the company has manufacturing certifications that are closer to the industry standard than the one favored by the third-party ESG vendor. Moreover the company has had no recent product recalls.

Based on our analysis and regular company engagement that helps reinforce our research conviction, we concluded that the third-party ESG rating overstates the risk profile of Jiangsu Hengrui as the company is subject to increased oversight from both Chinese and global regulators.

We followed up with the company in September 2020 mainly to discuss how government negotiations were progressing for the National Reimbursed Drug List (NRDL) as well as updates on GPO for generics and injectibles. Inclusion in the NRDL for Hengrui’s PD-1 will decide the price the company can charge for government reimbursement, impacting how broadly the treatment can be distributed. While we maintained our favorable view on the company, we did not alter our position size as we believe it appropriately reflects Jiangsu Hengrui’s risk/reward profile.

 

The specific security identified and described does not represent all of the securities purchased, sold, or recommended for advisory clients, and it should not be assumed that investment in the security identified and discussed was or will be profitable. This security was selected as we believe it aptly illustrates how Jennison integrates ESG considerations as part of our investment process. 

  • About Us

    • About Jennison

    • Firm Profile

    • Approach to Investing

    • Contact Us

  • Other Resources

    • Form CRS

Jennison Associates logo
  • Terms & Conditions
  • PGIM Privacy Center
  • Accessibility Help

Jennison Associates LLC. All Rights Reserved.

This website is intended for Institutional and Professional Investors only. All investments involve risk, including the possible loss of capital.

Important Disclosures

Jennison Associates is a registered investment advisor and a Prudential Financial company. Jennison Associates LLC has not been licensed or registered to provide investment services in any jurisdiction outside the United States. Certain investment vehicles are distributed or offered through Prudential Investment Management Services LLC (also a Prudential Financial Company) or other affiliated entities. Additionally, vehicles may not be registered or available for investment in all jurisdictions.

Please click on this disclosure link for important information, including information on non-US jurisdictions.

This web site is not intended as an offer or solicitation with respect to the purchase or sale of any security or other financial instrument or any investment management services. It does not constitute investment advice, should not be used as the basis for any investment decision, and does not purport to provide any legal, tax or accounting advice. This is for informational and educational purposes only and should not be construed as investment advice or an offer or solicitation in respect of any products or services to any persons who are prohibited from receiving such information under the laws applicable to their place of citizenship, domicile or residence.

Any views or opinions expressed on this website reflect the opinions of Jennison investment professionals at the time they are made and are subject to change.

Your investment objectives, risk tolerance, and liquidity needs must be reviewed before suitable programs can be recommended. Asset allocation and diversification strategies do not assure a profit or protect against loss in declining markets. Investors should consult with their attorney, accountant, and/or tax professional for advice concerning their particular situation.

Please remember that there are inherent risks involved with investing in the markets, and your investments may be worth more or less than your initial investment upon redemption. There is no guarantee that the investment managers’ objectives will be achieved. Further, there is no assurance that any strategies, methods, sectors, or any investment programs herein were or will prove to be profitable, or that any investment recommendations or decisions we make in the future will be profitable for any investor or client. Professional money management is not suitable for all investors.

Information for persons in the United Kingdom and various European Economic Area jurisdictions
In the United Kingdom, information is issued by PGIM Limited with registered office: Grand Buildings, 1-3 Strand, Trafalgar Square, London, WC2N 5HR. PGIM Limited is authorised and regulated by the Financial Conduct Authority (“FCA”) of the United Kingdom (Firm Reference Number 193418). In the European Economic Area (“EEA”), information is issued by PGIM Netherlands B.V. with registered office: Gustav Mahlerlaan 1212, 1081 LA  Amsterdam, The Netherlands. PGIM Netherlands B.V. is authorised by the Autoriteit Financiële Markten (“AFM”) in the Netherlands (Registration number 15003620) and operating on the basis of a European passport. In certain EEA countries, information is, where permitted, presented by PGIM Limited in reliance of provisions, exemptions or licenses available to PGIM Limited under temporary permission arrangements following the exit of the United Kingdom from the European Union. Jennison Associates LLC, PGIM Limited & PGIM Netherlands B.V. are wholly owned subsidiaries of PGIM, Inc. the principal investment management business of Prudential Financial, Inc. (‘PFI’).  PFI of the United States is not affiliated in any manner with Prudential plc, incorporated in the United Kingdom or with Prudential Assurance Company, a subsidiary of M&G plc, incorporated in the United Kingdom. These materials are issued by PGIM Limited and/or PGIM Netherlands B.V. to persons who are professional clients as defined  under the rules of the FCA and/or to persons who are professional clients as defined in the relevant local implementation of Directive 2014/65/EU (MiFID II).

Links to third-party sites are intended for informational purposes only and should not be considered investment advice or recommendation to invest. These links do not constitute endorsement or confirm their accuracy, and we are not responsible for any third-party guidelines, security, or accuracy of information.